Answers are grounded in this paper and cite their sources.
BACKGROUND: We aimed to describe 1-year outcomes of eyes switched to faricimab from first-generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) in routine care. METHODS: Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness! registry switched to faricimab from aflibercept 2 mg, ranibizumab, or bevacizumab between 1st January-1st August 2023 in Australia. RESULTS: One-year completion rates were high (335/383 [88%]). The proportion of choroidal neovascular (CNV) lesions graded as inactive increased from 39% at switch to 63% at 12 months (p < 0.01). Mean visual acuity (95% Confidence Interval) decreased from 70.0 (68.6, 71.5) to 68.4 (66.7, 70.1) logarithm of the minimum angle of resolution letters (both approx. 6/12). Mean treatment intervals increased from 7.2 to 10.5 weeks (p < 0.01). Eyes with active CNV at switch maintained mean VA -0.5 (-1.7, +0.7) letters; 50% were inactivated at 12 months. Eyes with inactive CNV at switch lost -3.5 (-5.0, -1.9) letters; 15% had reactivation at 12 months. Switchback occurred in 64/383 eyes (17%), predominantly to aflibercept 2 mg, that lost -1.9 letters without interval change at 12 months. Adverse outcomes were in keeping with previous reports, with no cases of occlusive retinal vasculitis. CONCLUSIONS: We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.
No takes yet. Share an insight, caveat, or question.
Hunt et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: